Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm

Abstract excerpt

An activating JAK2V617F mutation has been found in ∼50% patients with myelofibrosis (MF). Inactivating mutations in histone methyltransferase enhancer of zeste homolog 2 (EZH2) also have been observed in patients with MF. Interestingly, inactivating EZH2 mutations are often associated with JAK2V617F mutation in MF, although their contributions in the pathogenesis of MF remain elusive. To determine the effects of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Eosinophilic Disorders and Syndromes
• Share to Kruppel-like factors research
• Share to Myeloproliferative Neoplasms: Diagnosis and Treatment